Takeda Pharmaceutical Company Limited announced that results from the primary endpoint analysis of the ongoing pivotal Phase III Tetravalent Immunization...
Takeda Pharmaceutical Company Limited announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study...
Johnson & Johnson announced it is discontinuing the Phase II field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years
Sanofi Pasteur, the vaccines division of Sanofi announced that its tetravalent Dengue Vaccine candidate demonstrated proof of efficacy against Dengue,...
The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the 18 October 2018,...
Takeda announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine Qdenga (Dengue Tetravalent Vaccine) or TAK 003, for the prevention of dengue disease in individuals from four years of age in the European Union (EU)
Sanofi Pasteur, the vaccines division of Sanofi announced that the final landmark phase III efficacy study of its Dengue vaccine...
Sanofi Pasteur, the vaccines division of Sanofi has announced that the first of two pivotal Phase III efficacy studies with...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing...
Sanofi Pasteur, the vaccines division of Sanofi has announced the publication in The Lancet of the detailed results of its...